Sienna’s core activities focus on the clinical translation of biomarkers using novel diagnostic technologies. When a biomarker has been identified that offers solutions to genuine unmet needs in the pathology laboratory, Sienna will use its in-house expertise in collaboration with an external network of scientific and clinical partners to develop and commercialise a suitable product for the detection of that biomarker.
The team puts high importance on creating products that:
Sienna develops and commercialises clinically useful tests that solve unmet needs in the pathology diagnostics market.
Utilising the strong capabilities within the company for development and commercialisation of clinically useful, novel biomarker
detection technology, Sienna continually evaluates opportunities for additions to its R&D pipeline. Where there is
an identified biomarker that requires the work of an experienced team to develop a viable product for the routine detection
of that biomarker, Sienna is ideally positioned to bring that product to market.